Evidence of a significant role for Fas-mediated apoptosis in HCV clearance during pegylated interferon plus ribavirin combination therapy
Autor(a) principal: | |
---|---|
Data de Publicação: | 2011 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://repositorio.unifesp.br/handle/11600/33237 http://dx.doi.org/10.3851/IMP1768 |
Resumo: | Background: the role of apoptosis in treatment-induced HCV clearance is controversial. We sought to assess the kinetics of serum apoptosis-related cytokines during pegylated interferon-alpha 2a or -alpha 2b plus weight-based ribavirin therapy for genotype 1 chronic HCV infection.Methods: Serum levels of soluble Fas (sFas), soluble Fas ligand (sFasL) and soluble tumour necrosis factor receptor I (sTNF-RI) were measured at baseline, week 12 and 24 weeks after the end of therapy.Results: Sustained virological response (SVR) was achieved in 46% of the 164 included patients, 29% had a non-response (NR) and 25% had relapse (RR). NR patients presented with higher levels of sFasL at baseline and lower levels of sTNF-RI at week 12 as compared to RR and SVR patients. Lower concentrations of sFas were observed in SVR patients 24 weeks after treatment as compared to RR and NR patients. An increase in sFas at week 12 followed by a significant drop 24 weeks after therapy was observed among SVR patients. An increase in sFasL during and after treatment was observed in RR and SVR patients. NR patients exhibited an earlier drop in sTNF-RI levels as compared to RR and SVR patients.Conclusions: Virological response during HCV therapy was associated with an increase of sFas and sFasL, and maintenance of increased concentrations of sTNF-RI. |
id |
UFSP_b8a4dc93c7f67aaec89f5367e552c830 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br:11600/33237 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Schiavon, Leonardo de Lucca [UNIFESP]Narciso-Schiavon, Janaína Luz [UNIFESP]Carvalho-Filho, Roberto José de [UNIFESP]Sampaio, Juliana P. [UNIFESP]El Batah, Philipe N. [UNIFESP]Silva, Genimari A. [UNIFESP]Carvente, Claudia T. [UNIFESP]Silva, Antonio Eduardo Benedito [UNIFESP]Ferraz, Maria Lucia Gomes [UNIFESP]Universidade Federal de São Paulo (UNIFESP)2016-01-24T14:05:54Z2016-01-24T14:05:54Z2011-01-01Antiviral Therapy. London: Int Medical Press Ltd, v. 16, n. 3, p. 291-298, 2011.1359-6535http://repositorio.unifesp.br/handle/11600/33237http://dx.doi.org/10.3851/IMP176810.3851/IMP1768WOS:000294375600002Background: the role of apoptosis in treatment-induced HCV clearance is controversial. We sought to assess the kinetics of serum apoptosis-related cytokines during pegylated interferon-alpha 2a or -alpha 2b plus weight-based ribavirin therapy for genotype 1 chronic HCV infection.Methods: Serum levels of soluble Fas (sFas), soluble Fas ligand (sFasL) and soluble tumour necrosis factor receptor I (sTNF-RI) were measured at baseline, week 12 and 24 weeks after the end of therapy.Results: Sustained virological response (SVR) was achieved in 46% of the 164 included patients, 29% had a non-response (NR) and 25% had relapse (RR). NR patients presented with higher levels of sFasL at baseline and lower levels of sTNF-RI at week 12 as compared to RR and SVR patients. Lower concentrations of sFas were observed in SVR patients 24 weeks after treatment as compared to RR and NR patients. An increase in sFas at week 12 followed by a significant drop 24 weeks after therapy was observed among SVR patients. An increase in sFasL during and after treatment was observed in RR and SVR patients. NR patients exhibited an earlier drop in sTNF-RI levels as compared to RR and SVR patients.Conclusions: Virological response during HCV therapy was associated with an increase of sFas and sFasL, and maintenance of increased concentrations of sTNF-RI.Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Universidade Federal de São Paulo, Hepatitis Sect, Div Gastroenterol, São Paulo, BrazilUniversidade Federal de São Paulo, Hepatitis Sect, Div Gastroenterol, São Paulo, BrazilWeb of Science291-298engInt Medical Press LtdAntiviral TherapyEvidence of a significant role for Fas-mediated apoptosis in HCV clearance during pegylated interferon plus ribavirin combination therapyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP11600/332372022-06-02 10:24:18.252metadata only accessoai:repositorio.unifesp.br:11600/33237Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652023-05-25T12:16:48.819939Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.en.fl_str_mv |
Evidence of a significant role for Fas-mediated apoptosis in HCV clearance during pegylated interferon plus ribavirin combination therapy |
title |
Evidence of a significant role for Fas-mediated apoptosis in HCV clearance during pegylated interferon plus ribavirin combination therapy |
spellingShingle |
Evidence of a significant role for Fas-mediated apoptosis in HCV clearance during pegylated interferon plus ribavirin combination therapy Schiavon, Leonardo de Lucca [UNIFESP] |
title_short |
Evidence of a significant role for Fas-mediated apoptosis in HCV clearance during pegylated interferon plus ribavirin combination therapy |
title_full |
Evidence of a significant role for Fas-mediated apoptosis in HCV clearance during pegylated interferon plus ribavirin combination therapy |
title_fullStr |
Evidence of a significant role for Fas-mediated apoptosis in HCV clearance during pegylated interferon plus ribavirin combination therapy |
title_full_unstemmed |
Evidence of a significant role for Fas-mediated apoptosis in HCV clearance during pegylated interferon plus ribavirin combination therapy |
title_sort |
Evidence of a significant role for Fas-mediated apoptosis in HCV clearance during pegylated interferon plus ribavirin combination therapy |
author |
Schiavon, Leonardo de Lucca [UNIFESP] |
author_facet |
Schiavon, Leonardo de Lucca [UNIFESP] Narciso-Schiavon, Janaína Luz [UNIFESP] Carvalho-Filho, Roberto José de [UNIFESP] Sampaio, Juliana P. [UNIFESP] El Batah, Philipe N. [UNIFESP] Silva, Genimari A. [UNIFESP] Carvente, Claudia T. [UNIFESP] Silva, Antonio Eduardo Benedito [UNIFESP] Ferraz, Maria Lucia Gomes [UNIFESP] |
author_role |
author |
author2 |
Narciso-Schiavon, Janaína Luz [UNIFESP] Carvalho-Filho, Roberto José de [UNIFESP] Sampaio, Juliana P. [UNIFESP] El Batah, Philipe N. [UNIFESP] Silva, Genimari A. [UNIFESP] Carvente, Claudia T. [UNIFESP] Silva, Antonio Eduardo Benedito [UNIFESP] Ferraz, Maria Lucia Gomes [UNIFESP] |
author2_role |
author author author author author author author author |
dc.contributor.institution.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Schiavon, Leonardo de Lucca [UNIFESP] Narciso-Schiavon, Janaína Luz [UNIFESP] Carvalho-Filho, Roberto José de [UNIFESP] Sampaio, Juliana P. [UNIFESP] El Batah, Philipe N. [UNIFESP] Silva, Genimari A. [UNIFESP] Carvente, Claudia T. [UNIFESP] Silva, Antonio Eduardo Benedito [UNIFESP] Ferraz, Maria Lucia Gomes [UNIFESP] |
description |
Background: the role of apoptosis in treatment-induced HCV clearance is controversial. We sought to assess the kinetics of serum apoptosis-related cytokines during pegylated interferon-alpha 2a or -alpha 2b plus weight-based ribavirin therapy for genotype 1 chronic HCV infection.Methods: Serum levels of soluble Fas (sFas), soluble Fas ligand (sFasL) and soluble tumour necrosis factor receptor I (sTNF-RI) were measured at baseline, week 12 and 24 weeks after the end of therapy.Results: Sustained virological response (SVR) was achieved in 46% of the 164 included patients, 29% had a non-response (NR) and 25% had relapse (RR). NR patients presented with higher levels of sFasL at baseline and lower levels of sTNF-RI at week 12 as compared to RR and SVR patients. Lower concentrations of sFas were observed in SVR patients 24 weeks after treatment as compared to RR and NR patients. An increase in sFas at week 12 followed by a significant drop 24 weeks after therapy was observed among SVR patients. An increase in sFasL during and after treatment was observed in RR and SVR patients. NR patients exhibited an earlier drop in sTNF-RI levels as compared to RR and SVR patients.Conclusions: Virological response during HCV therapy was associated with an increase of sFas and sFasL, and maintenance of increased concentrations of sTNF-RI. |
publishDate |
2011 |
dc.date.issued.fl_str_mv |
2011-01-01 |
dc.date.accessioned.fl_str_mv |
2016-01-24T14:05:54Z |
dc.date.available.fl_str_mv |
2016-01-24T14:05:54Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Antiviral Therapy. London: Int Medical Press Ltd, v. 16, n. 3, p. 291-298, 2011. |
dc.identifier.uri.fl_str_mv |
http://repositorio.unifesp.br/handle/11600/33237 http://dx.doi.org/10.3851/IMP1768 |
dc.identifier.issn.none.fl_str_mv |
1359-6535 |
dc.identifier.doi.none.fl_str_mv |
10.3851/IMP1768 |
dc.identifier.wos.none.fl_str_mv |
WOS:000294375600002 |
identifier_str_mv |
Antiviral Therapy. London: Int Medical Press Ltd, v. 16, n. 3, p. 291-298, 2011. 1359-6535 10.3851/IMP1768 WOS:000294375600002 |
url |
http://repositorio.unifesp.br/handle/11600/33237 http://dx.doi.org/10.3851/IMP1768 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Antiviral Therapy |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
291-298 |
dc.publisher.none.fl_str_mv |
Int Medical Press Ltd |
publisher.none.fl_str_mv |
Int Medical Press Ltd |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
|
_version_ |
1783460271082176512 |